T-cell activation in the intestinal mucosa

Immunological Reviews

Volumn 215, Issue 1, 2007, Pages 189-201

  Montufar Solis, Dina ^a   Garza, Tomas ^a   Klein, John R ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b Dental Branch   (United States)

Author keywords

Costimulation; Epithelium; Intraepithelial lymphocyte; Regulation; T cell

Indexed keywords

CD3 ANTIGEN; CD69 ANTIGEN; CHEMOKINE; CYTOKINE; GLYCOPROTEIN; INTERLEUKIN 12; INTERLEUKIN 18 RECEPTOR; LEUKOSIALIN; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

CELL DEATH; CYTOTOXICITY; EFFECTOR CELL; HUMAN; INTESTINE EPITHELIUM; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA; LARGE INTESTINE; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; REVIEW; SMALL INTESTINE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; EPITHELIAL CELLS; HUMANS; IMMUNITY, MUCOSAL; INTESTINAL MUCOSA; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES;

EID: 33846849409     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2006.00471.x     Document Type: Review

References (145)

1. Poussier P, Julius M. Thymus independent T cell development and selection in the intestinal epithelium. Annu Rev Immunol 1994;12:521-553.
2. Rocha B, Vassalli P, Guy-Grand D. The Vβ repertoire of mouse gut homodimeric α CD8+ intraepithelial T cell receptor α/β + lymphocytes reveals a major extrathymic pathway of T cell differentiation. J Exp Med 1991;173:483-486.
3. Rocha B, Guy-Grand D, Vassalli P. Extrathymic T cell differentiation. Curr Opin Immunol 1995;7:235-242.
4. Cheroutre H. IELs: enforcing law and order in the court of the intestinal epithelium. Immunol Rev 2005;206:114-131.
5. Parrott DM, Tait C, MacKenzie S, Mowat AM, Davies MD, Micklem HS. Analysis of the effector functions of different populations of mucosal lymphocytes. Ann NY Acad Sci 1983;409:307-320.
6. Tagliabue A, Befus AD, Clark DA, Bienenstock J. Characteristics of natural killer cells in the murine intestinal epithelium and lamina propria. J Exp Med 1982;155:1785-1796.
7. Petit A, et al. Murine intestinal intraepithelial lymphocytes I. Relationship of a novel Thy-1-,Lyt-1-,Lyt-2+, granulated subpopulation to natural killer cells and mast cells. Eur J Immunol 1985;15:211-215.
8. Cerf-Bensussan N, Guy-Grand D, Griscelli C. Intraepithelial lymphocytes of human gut: isolation, characterisation and study of natural killer activity. Gut 1985;26:81-88.
9. Viney JL, Kilshaw PJ, MacDonald TT. Cytotoxic α/β+ and γ/δ+ T cells in murine intestinal epithelium. Eur J Immunol 1990;20:1623-1626.
10. Klein JR. Ontogeny of the Thy-1-, Lyt-2+ murine intestinal intraepithelial lymphocyte. Characterization of a unique population of thymus-independent cytotoxic effector cells in the intestinal mucosa. J Exp Med 1986;164:309-314.
11. Lefrancois L, Goodman T. In vivo modulation of cytolytic activity and Thy-1 expression in TCR-gamma delta+ intraepithelial lymphocytes. Science 1989;243:1716-1718.
12. Mosley RL, Styre D, Klein JR. Differentiation and functional maturation of bone marrow-derived intestinal epithelial T cells expressing membrane T cell receptor in athymic radiation chimeras. J Immunol 1990;145:1369-1375.
13. Tsujimura K, et al. Characterization of murine CD160+ CD8+ T lymphocytes. Immunol Lett 2006;106:48-56.
14. Wang HC, Klein JR. Multiple levels of activation of murine CD8+ intraepithelial lymphocytes defined by OX40 (CD134) expression: effects on cell-mediated cytotoxicity, IFN-γ, and IL-10 regulation. J Immunol 2001;167:6717-6723.
15. Wang HC, Zhou Q, Dragoo J, Klein JR. Most murine CD8+ intestinal intraepithelial lymphocytes are partially but not fully activated T cells. J Immunol 2002;169:4717-4722.
16. Pahar B, Lackner AA, Veazey RS. Intestinal double-positive CD4+CD8+ T cells are highly activated memory cells with an increased capacity to produce cytokines. Eur J Immunol 2006;36:583-592.
17. Huleatt JW, Lefrancois L. Antigen-driven induction of CD11c on intestinal intraepithelial lymphocytes and CD8+ T cells in vivo. J Immunol 1995;154:5684-5693.
18. Kim SK, Reed DS, Heath WR, Carbone F, Lefrancois L. Activation and migration of CD8 T cells in the intestinal mucosa. J Immunol 1997;159:4295-4306.
19. Kawaguchi-Miyashita M, Shimada S, Matsuoka Y, Ohwaki M, Nanno M. Activation of T-cell receptor-γδ+ cells in the intestinal epithelia of KN6 transgenic mice. Immunology 2000;101:38-45.
20. Lee HO, Cooper CJ, Choi JH, Alnadjim Z, Barrett TA. The state of CD4+ T cell activation is a major factor for determining the kinetics and location of T cell responses to oral antigen. J Immunol 2002;168:3833-3838.
21. Shires J, Theodoridis E, Hayday AC. Biological insights into TCRγδ+ and TCRα/β+ intraepithelial lymphocytes provided by serial analysis of gene expression (SAGE). Immunity 2001;15:419-434.
22. Fahrer AM, et al. Attributes of γδ intraepithelial lymphocytes as suggested by their transcriptional profile. Proc Natl Acad Sci USA 2001;98:10261-10266.
23. Ohteki T, MacDonald HR. Expression of the CD28 costimulatory molecule on subsets of murine intestinal intraepithelial lymphocytes correlates with lineage and responsiveness. Eur J Immunol 1993;23:1251-1255.
24. Sillett HK, Southgate J, Howdle PD, Trejdosiewicz LK. Expression of activation and costimulatory elements by human intestinal intraepithelial lymphocytes. Scand J Immunol 1999;50:52-60.
25. O'Keeffe J, et al. Diverse populations of T cells with NK cell receptors accumulate in the human intestine in health and in colorectal cancer. Eur J Immunol 2004;34:2110-2119.
26. Sancho D, Gomez M, Sanchez-Madrid F. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol 2005;26:136-140.
27. Sancho D, et al. CD69 downregulates autoimmune reactivity through active TGF-β production in collagen-induced arthritis. J Clin Invest 2003;112:872-882.
28. Esplugues E, et al. Enhanced antitumor immunity in mice deficient in CD69. J Exp Med 2003;197:1093-1106.
29. Lauzurica P, et al. Phenotypic and functional characteristics of hematopoietic cell lineages in CD69-deficient mice. Blood 2000;95:2312- 2320.
30. Masopust D, et al. Activated primary and memory CD8 T cells migrate to nonlymphoid tissues regardless of site of activation or tissue of origin. J Immunol 2004;172:4875-4882.
31. Cima I, et al. Intestinal epithelial cells synthesize glucocorticoids and regulate T cell activation. J Exp Med 2004;200:1635-1646.
32. Nakamura K, et al. TGF-β 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol 2004;172:834-842.
33. Kulkarni AB, et al. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993;90:770-774.
34. Giladi E, Raz E, Karmeli F, Okon E, Rachmilewitz D. Transforming growth factor-beta gene therapy ameliorates experimental colitis in rats. Eur J Gastroenterol Hepatol 1995;7:341-347.
35. Maiza H, Leca G, Mansur IG, Schiavon V, Boumsell L, Bensussan A. A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity. J Exp Med 1993;178:1121-1126.
36. Anumanthan A, et al. Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes. J Immunol 1998;161:2780-2790.
37. Nikolova M, Marie-Cardine A, Boumsell L, Bensussan A. BY55/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression. Int Immunol 2002;14:445-451.
38. Agrawal S, et al. Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells. J Immunol 1999;162:1223-1226.
39. Moore T, Huang S, Terstappen LW, Bennett M, Kumar V. Expression of CD43 on murine and human pluripotent hematopoietic stem cells. J Immunol 1994;153:4978-4987.
40. Baecher CM, Infante AJ, Semcheski KL, Frelinger JG. Identification and characterization of a mouse cell surface antigen with alternative molecular forms. Immunogenetics 1988;28:295-302.
41. Gulley ML, Ogata LC, Thorson JA, Dailey MO, Kemp JD. Identification of a murine pan-T cell antigen which is also expressed during the terminal phases of B cell differentiation. J Immunol 1988;140:3751-3757.
42. Rosenstein Y, Santana A, Pedraza-Alva G. CD43, a molecule with multiple functions. Immunol Res 1999;20:89-99.
43. Jones AT, et al. Characterization of the activation-associated isoform of CD43 on murine T lymphocytes. J Immunol 1994;153:3426-3439.
44. Daniels MA, Hogquist KA, Jameson SC. Sweet 'n'; sour: the impact of differential glycosylation on T cell responses. Nat Immunol 2002;3:903- 910.
45. Woodman RC, et al. The functional paradox of CD43 in leukocyte recruitment: a study using CD43-deficient mice. J Exp Med 1998;188:2181- 2186.
46. Onami TM, et al. Dynamic regulation of T cell immunity by CD43. J Immunol 2002;168:6022-6031.
47. van den Berg TK, et al. Cutting edge: CD43 functions as a T cell counterreceptor for the macrophage adhesion receptor sialoadhesin (Siglec-1). J Immunol 2001;166:3637-3640.
48. Bagriacik EU, Tang M, Wang HC, Klein JR. CD43 potentiates CD3-induced proliferation of murine intestinal intraepithelial lymphocytes. Immunol Cell Biol 2001;79:303-307.
49. Montufar-Solis D, Garza T, Klein JR. Selective upregulation of immune regulatory and effector cytokine synthesis by intestinal intraepithelial lymphocytes following CD43 costimulation. Biochem Biophys Res Commun 2005;338:1158-1163.
50. Andoh A, et al. IL-17 selectively down-regulates TNF-α-induced RANTES gene expression in human colonic subepithelial myofibroblasts. J Immunol 2002;169:1683-1687.
51. McCormack G, Moriarty D, O'Donoghue DP, McCormick PA, Sheahan K, Baird AW. Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflamm Res 2001;50:491-495.
52. Mazzucchelli L, et al. Differential in situ expression of the genes encoding the chemokines MCP-1 and RANTES in human inflammatory bowel disease. J Pathol 1996;178:201-206.
53. Mosley RL, Hamad M, Whetsell M, Klein JR. A novel marker of murine bone marrow hematopoietic stem cells that is expressed on peripheral T cells and is associated with a functionally important molecule on activated cytotoxic T lymphocytes. Hybridoma 1994;13:353-358.
54. Sperling AI, et al. CD43 is a murine T cell costimulatory receptor that functions independently of CD28. J Exp Med 1995;182:139-146.
55. Wang HC, Montufar-Solis D, Teng BB, Klein JR. Maximum immunobioactivity of murine small intestinal intraepithelial lymphocytes resides in a subpopulation of CD43+ T cells. J Immunol 2004;173:6294-6302.
56. Montufar-Solis D, Garza T, Teng BB, Klein JR. Upregulation of ICOS on CD43+ CD4+ murine small intestinal intraepithelial lymphocytes during acute reovirus infection. Biochem Biophys Res Commun 2006;342:782-790.
57. high T cells. Eur J Immunol 2001;31:1465-1474.
58. Andres PG, et al. Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine. J Immunol 2000;164:6303-6312.
59. Agace WW, Roberts AI, Wu L, Greineder C, Ebert EC, Parker CM. Human intestinal lamina propria and intraepithelial lymphocytes express receptors specific for chemokines induced by inflammation. Eur J Immunol 2000;30:819-826.
60. Banks C, Bateman A, Payne R, Johnson P, Sheron N. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol 2003;199:28-35.
61. Bagriacik EU, Armstrong MD, Okabe M, Klein JR. Differential expression of CD43 isoforms on murine T cells and their relationship to acute intestinal graft versus host disease: studies using enhanced-green fluorescent protein transgenic mice. Int Immunol 1999;11:1651-1662.
62. Okamura H, et al. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 1995;378:88-91.
63. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001;19:423-474.
64. Lochner M, Forster I. Anti-interleukin-18 therapy in murine models of inflammatory bowel disease. Pathobiology 2002;70:164-169.
65. Yoshimoto T, et al. IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci U S A 1999;96:13962-13966.
66. Hoshino T, Wiltrout RH, Young HA. IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J Immunol 1999;162:5070-5077.
67. Yoshimoto T, et al. IL-18 induction of IgE: dependence on CD4+ T cells, IL-4 and STAT6. Nat Immunol 2000;1:132-137.
68. Zediak VP, Hunter CA. IL-10 fails to inhibit the production of IL-18 in response to inflammatory stimuli. Cytokine 2003;21:84-90.
69. Takagi H, et al. Contrasting action of IL-12 and IL-18 in the development of dextran sodium sulphate colitis in mice. Scand J Gastroenterol 2003;38:837-844.
70. Maxwell JR, et al. IL-18 bridges innate and adaptive immunity through IFN-γ and the CD134 pathway. J Immunol 2006;177:234-245.
71. Ueno N, et al. Role of interleukin 18 in nitric oxide production and pancreatic damage during acute pancreatitis. Shock 2005;24:564-570.
72. Okazawa A, et al. Human intestinal epithelial cell-derived interleukin (IL)-18, along with IL-2, IL-7 and IL-15, is a potent synergistic factor for the proliferation of intraepithelial lymphocytes. Clin Exp Immunol 2004;136:269-276.
73. Yang YJ, Wang ZY, Chen SH, Ge XR. Cloning and characterization of a new isoform of mouse interleukin-18. Acta Biochim Biophys Sin (Shanghai)2005;37:826-834.
74. Glas J, et al. Association of polymorphisms in the interleukin-18 gene in patients with Crohn's disease depending on the CARD15/NOD2 genotype. Inflamm Bowel Dis 2005;11:1031-1037.
75. Subramaniam S, Stansberg C, Cunningham C. The interleukin 1 receptor family. Dev Comp Immunol 2004;28:415-428.
76. Kato Z, et al. The structure and binding mode of interleukin-18. Nat Struct Biol 2003;10:966-971.
77. Born TL, Thomassen E, Bird TA, Sims JE. Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. J Biol Chem 1998;273:29445-29450.
78. Fantuzzi G, et al. Generation and characterization of mice transgenic for human IL-18-binding protein isoform a. J Leukoc Biol 2003;74:889-896.
79. Dinarello CA, Novick D, Rubinstein M, Lonnemann G. Interleukin 18 and interleukin 18 binding protein: possible role in immunosuppression of chronic renal failure. Blood Purif 2003;21:258-270.
80. Yoshimoto T, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-γ production. J Immunol 1998;161:3400-3407.
81. Kanai T, et al. Interleukin 18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohn';s disease. Gastroenterology 2000;119:1514-1523.
82. Takeuchi D, et al. Interleukin 18 causes hepatic ischemia/reperfusion injury by suppressing anti-inflammatory cytokine expression in mice. Hepatology 2004;39:699-710.
83. Tsutsui H, et al. IL-18 accounts for both TNF-α and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J Immunol 1997;159:3961-3967.
84. Faggioni R, et al. IL-18-binding protein protects against lipopolysaccharide- induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice. J Immunol 2001;167:5913- 5920.
85. Raeburn CD, et al. Neutralization of IL-18 attenuates lipopolysaccharide-induced myocardial dysfunction. Am J Physiol Heart Circ Physiol 2002;283:H650-H657.
86. Min CK, et al. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation. Blood 2004;104:3393- 3399.
87. Plater-Zyberk C, et al. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 2001;108:1825-1832.
88. Wirtz S, Becker C, Blumberg R, Galle PR, Neurath MF. Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA. J Immunol 2002;168:411-420.
89. Monteleone G, Fina D, Caruso R, Pallone F. New mediators of immunity and inflammation in inflammatory bowel disease. Curr Opin Gastroenterol 2006;22:361-364.
90. Reuter BK, Pizarro TT Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe? Eur J Immunol 2004;34:2347-2355.
91. Ludwiczek O, Kaser A, Novick D, Dinarello CA, Rubinstein M, Tilg H. Elevated systemic levels of free interleukin-18 (IL-18) in patients with Crohn's disease. Eur Cytokine Netw 2005;16:27-33.
92. Wiercinska-Drapalo A, Flisiak R, Jaroszewicz J, Prokopowicz D. Plasma interleukin-18 reflects severity of ulcerative colitis. World J Gastroenterol 2005;11:605-608.
93. Salvati VM, et al. Interleukin 18 and associated markers of T helper cell type 1 activity in coeliac disease. Gut 2002;50:186-190.
94. Alderson MR, et al. Molecular and biological characterization of human 4-1BB and its ligand. Eur J Immunol 1994;24:2219-2227.
95. Wilcox RA, Tamada K, Strome SE, Chen L. Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol 2002;169:4230-4236.
96. Zhou Z, Pollok KE, Kim KK, Kim YJ, Kwon BS. Functional analysis of T-cell antigen 4-1BB in activated intestinal intra-epithelial T lymphocytes. Immunol Lett 1994;41:177-184.
97. Zhou Z, et al. Characterization of human homologue of 4-1BB and its ligand. Immunol Lett 1995;45:67-73.
98. Vinay DS, Kwon BS. Role of 4-1BB in immune responses. Semin Immunol 1998;10:481-489.
99. Bukczynski J, Wen T, Watts TH. Costimulation of human CD28- T cells by 4-1BB ligand. Eur J Immunol 2003;33:446-454.
100. Croft M. Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev 2003;14:265-273.
101. DeBenedette MA, Shahinian A, Mak TW, Watts TH. Costimulation of CD28- T lymphocytes by 4-1BB ligand. J Immunol 1997;158:551-559.
102. Maerten P, et al. Involvement of 4-1BB (CD137)-4-1BB ligand interaction in the modulation of CD4 T cell-mediated inflammatory colitis. Clin Exp Immunol 2006;143:228-236.
103. Maerten P, et al. Functional expression of 4-1BB (CD137) in the inflammatory tissue in Crohn's disease. Clin Immunol 2004;112:239-246.
104. Murali-Krishna K, Ahmed R. Cutting edge: naive T cells masquerading as memory cells. J Immunol 2000;165:1733-1737.
105. Goldrath AW, Bogatzki LY, Bevan MJ. Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med 2000;192:557-564.
106. Havran WL, Fitch FW. Characterization of murine cytolytic-helper hybrid T cell clones. Nature 1987;325:65-67.
107. Mallett S, Fossum S, Barclay AN. Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes - a molecule related to nerve growth factor receptor. EMBO J 1990;9:1063-1068.
108. Paterson DJ, et al. Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol Immunol 1987;24:1281-1290.
109. Fujita T, Ukyo N, Hori T, Uchiyama T. Functional characterization of OX40 expressed on human CD8+ T cells. Immunol Lett 2006;106:27-33.
110. al-Shamkhani A, Birkeland ML, Puklavec M, Brown MH, James W, Barclay AN. OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand. Eur J Immunol 1996;26:1695-1699.
111. Dawicki W, Bertram EM, Sharpe AH, Watts TH. 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. J Immunol 2004;173:5944-5951.
112. Weinberg AD, Vella AT, Croft M. OX-40: life beyond the effector T cell stage. Semin Immunol 1998;10:471-480.
113. Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, Delespesse G. Expression and function of OX40 ligand on human dendritic cells. J Immunol 1997;159:3838-3848.
114. Lane P. Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells. J Exp Med 2000;191:201-206.
115. Souza HS, Elia CC, Spencer J, MacDonald TT. Expression of lymphocyte-endothelial receptor-ligand pairs, α4b7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut 1999;45:856-863.
116. Stuber E, Buschenfeld A, Luttges J, Von Freier A, Arendt T, Folsch UR. The expression of OX40 in immunologically mediated diseases of the gastrointestinal tract (celiac disease, Crohn's disease, ulcerative colitis). Eur J Clin Invest 2000;30:594-599.
117. Stuber E, Von Freier A, Marinescu D, Folsch UR. Involvement of OX40-OX40L interactions in the intestinal manifestations of the murine acute graft-versus-host disease. Gastroenterology 1998;115:1205-1215.
118. Tsukada N, Akiba H, Kobata T, Aizawa Y, Yagita H, Okumura K. Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation. Blood 2000;95:2434-2439.
119. Totsuka T, et al. Therapeutic effect of anti-OX40L and anti-TNF-α MAbs in a murine model of chronic colitis. Am J Physiol Gastrointest Liver Physiol 2003;284:G595-G603.
120. Obermeier F, et al. OX40/OX40L interaction induces the expression of CXCR5 and contributes to chronic colitis induced by dextran sulfate sodium in mice. Eur J Immunol 2003;33:3265-3274.
121. Hutloff A, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999;397:263-266.
122. Subudhi SK, Alegre ML, Fu YX. The balance of immune responses: costimulation verse coinhibition. J Mol Med 2005;83:193-202.
123. Yoshinaga SK, et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature 1999;402:827-832.
124. Sato T, et al. Hyperexpression of inducible costimulator and its contribution on lamina propria T cells in inflammatory bowel disease. Gastroenterology 2004;126:829-839.
125. Totsuka T, et al. Ameliorating effect of anti-inducible costimulator monoclonal antibody in a murine model of chronic colitis. Gastroenterology 2003;124:410-421.
126. Ishii K, et al. Hyperexpression of inducible costimulator on lamina propria mononuclear cells in rat dextran sulfate sodium colitis. J Gastroenterol Hepatol 2004;19:174-181.
127. Nakazawa A, et al. The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology 2004;126:1347-1357.
128. Kanai T, Totsuka T, Tezuka K, Watanabe M. ICOS costimulation in inflammatory bowel disease. J Gastroenterol 2002;37 (Suppl. 14):78-81.
129. Dong C, et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 2001;409:97-101.
130. Tafuri A, et al. ICOS is essential for effective T-helper-cell responses. Nature 2001;409:105-109.
131. Mosley RL, Whetsell M, Klein JR. Proliferative properties of murine intestinal intraepithelial lymphocytes (IEL): IEL expressing TCR αβ or TCR γδ are largely unresponsive to proliferative signals mediated via conventional stimulation of the CD3-TCR complex. Int Immunol 1991;3:563-569.
132. Sydora BC, et al. Intestinal intraepithelial lymphocytes are activated and cytolytic but do not proliferate as well as other T cells in response to mitogenic signals. J Immunol 1993;150:2179-2191.
133. Wang T, Langley KE, Gourley WK, Klimpel GR. Stem cell factor (SCF) can regulate the activation and expansion of murine intraepithelial lymphocytes. Cytokine 2000;12:272-280.
134. Laky K, Lefrancois L, Puddington L. Age-dependent intestinal lymphoproliferative disorder due to stem cell factor receptor deficiency: parameters in small and large intestine. J Immunol 1997;158:1417-1427.
135. Hirose K, et al. Interleukin-15 may be responsible for early activation of intestinal intraepithelial lymphocytes after oral infection with Listeria monocytogenes in rats. Infect Immun 1998;66:5677-5683.
136. Ebert EC. Interleukin 15 is a potent stimulant of intraepithelial lymphocytes. Gastroenterology 1998;115:1439-1445.
137. Puddington L, Olson S, Lefrancois L. Interactions between stem cell factor and c-kit are required for intestinal immune system homeostasis. Immunity 1994;1:733-739.
138. Wang T, Alam R, Langley KE, Klimpel GR. Stem cell factor and IL-2 act synergistically in inducing intraepithelial lymphocyte proliferation and cytokine production: upregulation of the IL-2 receptor gamma-chain and signaling via JAK-3. Cell Immunol 2000;205:62-71.
139. Jung HC, et al. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest 1995;95:55-65.
140. Sperber K, Silverstein L, Brusco C, Yoon C, Mullin GE, Mayer L. Cytokine secretion induced by superantigens in peripheral blood mononuclear cells, lamina propria lymphocytes, and intraepithelial lymphocytes. Clin Diagn Lab Immunol 1995;2:473-477.
141. Kaser A, et al. Natural killer T cells in mucosal homeostasis. Ann NY Acad Sci 2004;1029:154-168.
142. Ebert EC. Inhibitory effects of transforming growth factor-β (TGF-β) on certain functions of intraepithelial lymphocytes. Clin Exp Immunol 1999;115:415-420.
143. Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 1996;110:975-984.
144. Sellon RK, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998;66:5224-5231.
145. Schwerbrock NM, et al. Interleukin 10-deficient mice exhibit defective colonic Muc2 synthesis before and after induction of colitis by commensal bacteria. Inflamm Bowel Dis 2004;10:811-823.